摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-甲基苯并咪唑 | 6478-73-5

中文名称
5-甲基苯并咪唑
中文别名
5,6-二氯苯并咪唑;5,6-二氯苯咪唑
英文名称
5,6-dichlorobenzimidazole
英文别名
5,6-dichloro-1H-benzo[d]imidazole;5,6-dichloro-1H-benzimidazole
5-甲基苯并咪唑化学式
CAS
6478-73-5
化学式
C7H4Cl2N2
mdl
——
分子量
187.028
InChiKey
IPRDZAMUYMOJTA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    205-206°
  • 沸点:
    426.9±25.0 °C(Predicted)
  • 密度:
    1.571±0.06 g/cm3(Predicted)
  • 溶解度:
    可溶于DMSO(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36
  • 危险类别码:
    R36/37/38
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    室温且干燥

SDS

SDS:5a08f3568dad849f9af267763be01f15
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5,6-Dichlorobenzimidazole
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5,6-Dichlorobenzimidazole
CAS number: 6478-73-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4Cl2N2
Molecular weight: 187

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-甲基苯并咪唑吡啶N-甲基咪唑2,4,6-三异丙基苯磺酰氯sodium methylate 作用下, 以 吡啶甲醇 为溶剂, 25.0~180.0 ℃ 、2.67 kPa 条件下, 反应 39.0h, 生成 5,6-dichloro-1-β-D-ribofuranosylbenzimidazolyl-(2'->5')-5,6-dichloro-1-β-D-ribofuranosylbenzimidazole triethylammonium salt
    参考文献:
    名称:
    5,6-二氯苯并咪唑2'→5'-和3'→5'-核苷酸二聚体和三聚体的合成及性质
    摘要:
    通过融合法合成的5,6-二氯-1-β-D-呋喃呋喃糖基苯并咪唑(2)用于合成2'---- 5'-和3'---- 5'-连接的二-和三聚体寡核苷酸。所用的保护基团是对HO-5′为对甲氧基三苯甲基,对HO-2′,3′为叔丁基二甲基甲硅烷基,对磷酸酯基为2,5-二氯苯基和2-(4-硝基苯基)乙基。通过磷酸三酯方法建立核苷酸间键,以得到完全保护的2'---- 5'二聚体(15、17和18)和三聚体(27和28),以及3'---- 5二聚体(22和23)和三聚体(31和32)。脱保护涉及一系列步骤,以高收率得到相应的游离寡核苷酸21、26、30和33,其被分离为三乙铵盐。
    DOI:
    10.1016/0008-6215(92)84178-u
  • 作为产物:
    描述:
    4,5-二氯-2-硝基苯胺二氧化硫脲 、 sodium hydroxide 作用下, 反应 6.0h, 生成 5-甲基苯并咪唑
    参考文献:
    名称:
    Mechanochemistry Frees Thiourea Dioxide (TDO) from the ‘Veils’ of Solvent, Exposing All Its Reactivity
    摘要:
    氮基杂环的合成一直被认为是开发医药和农业药物的关键。这也是近几十年来提出各种合成方法的原因。然而,这些方法通常条件苛刻,或需要使用有毒溶剂和危险试剂。机械化学无疑是目前最有前途的技术之一,可用于减少可能对环境造成的影响,从而解决全球对环境污染问题的关注。根据这一思路,我们提出了一种利用二氧化硫脲(TDO)的还原性和亲电性合成各种杂环类化合物的新机械化学方案。同时利用二氧化硫脲(TDO)这种纺织工业成分的低成本以及机械化学这种绿色技术所带来的所有优势,我们为制备杂环类化合物规划了一条更具可持续性和生态友好型的方法路线。
    DOI:
    10.3390/molecules28052239
点击查看最新优质反应信息

文献信息

  • Cobalamin conjugates for anti-tumor therapy
    申请人:Weinshenker M. Ned
    公开号:US20050054607A1
    公开(公告)日:2005-03-10
    The present invention provides a cobalamin-drug conjugate suitable for the treatment of tumor related diseases. Cobalamin is indirectly covalently bound to an anti-tumor drug via a cleavable linker and one or more optional spacers. Cobalamin is covalently bound to a first spacer or the cleavable linker via the 5′-OH of the cobalamin ribose ring. The drug is bound to a second spacer of the cleavable linker via an existing or added functional group on the drug. After administration, the conjugate forms a complex with transcobalamin (any of its isoforms). The complex then binds to a receptor on a cell membrane and is taken up into the cell. Once in the cell, an intracellular enzyme cleaves the conjugate thereby releasing the drug. Depending upon the structure of the conjugate, a particular class or type of intracellular enzyme affects the cleavage. Due to the high demand for cobalamin in growing cells, tumor cells typically take up a higher percentage of the conjugate than do normal non-growing cells. The conjugate of the invention advantageously provides a reduced systemic toxicity and enhanced efficacy as compared to a corresponding free drug.
    本发明提供了一种适用于治疗肿瘤相关疾病的钴胺素-药物结合物。钴胺素通过可切割的连接剂间接共价结合到抗肿瘤药物上,还可以通过一个或多个可选的间隔物。钴胺素通过其核糖环的5'-OH与第一间隔物或可切割连接剂共价结合。药物通过其现有或添加的功能基团与可切割连接剂的第二间隔物结合。在给药后,结合物与转钴胺素(其任何同工异构体)形成复合物。然后,该复合物结合到细胞膜上的受体并被细胞摄取。一旦进入细胞,细胞内酶将切割结合物,从而释放药物。根据结合物的结构,特定类别或类型的细胞内酶影响切割。由于生长细胞对钴胺素的需求量较高,肿瘤细胞通常摄取结合物的比例高于正常非生长细胞。本发明的结合物与相应的游离药物相比,具有较低的全身毒性和增强的疗效。
  • [EN] NOVEL ANTIVIRAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTIVIRAUX
    申请人:PHARMARESOURCES SHANGHAI CO LTD
    公开号:WO2012065062A1
    公开(公告)日:2012-05-18
    The present invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection such as HIV using the same.
    本发明涉及一种化合物I的化学式:或其药用可接受的盐,其中符号如规范中定义;包括相同化合物的药物组合物,以及使用该化合物治疗或预防病毒感染,如HIV的方法。
  • Src kinase inhibitor compounds
    申请人:Merck & Co., Inc.
    公开号:US06498165B1
    公开(公告)日:2002-12-24
    Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.
    嘧啶化合物(化学式I),或其药用可接受的盐、水合物、溶剂合物、晶型和单一对映异构体,以及包括这些化合物的药物组合物,它们是酪氨酸激酶酶的抑制剂,因此在预防和治疗蛋白酪氨酸激酶相关疾病方面具有用处,如免疫疾病、高增殖性疾病和其他认为不当的蛋白激酶作用可能起作用的疾病,如癌症、血管生成、动脉粥样硬化、移植排斥、类风湿性关节炎和牛皮癣。
  • Endogenous X–CO species enable catalyst-free formylation prerequisite for CO<sub>2</sub> reductive upgrading
    作者:Hongguo Wu、Wenshuai Dai、Shunmugavel Saravanamurugan、Hu Li、Song Yang
    DOI:10.1039/d0gc02142c
    日期:——
    (>90%) from catalyst-free reductive upgrading of CO2 under mild conditions (50 °C). The endogenous X–CO species, derived from the N-methyl-substituted amide-based solvent [Me2N–C(O)–R], especially PolarClean, and O-formyl group [O–C(O)–H] of in situ formed silyl formate, were found to play a prominent promotional role in the activation of the used hydrosilane for reductive CO2 insertion, as demonstrated
    CO 2是温室气体的主要成分,目前已被开发为一种有前途的碳原料替代品。在各种转化途径中,经历催化还原的CO 2可以提供氢/能量载体和增值化学品,而特定的含金属催化剂或有机催化剂通常是顺利进行所涉及的反应过程的先决条件。在这项工作中,可以在温和的条件下通过无催化剂的CO 2还原提质,以高收率(> 90%)合成甲酸和含N的苯并杂环化合物(包括各种苯并咪唑,苯并噻唑和苯并恶唑)以及硅烷醇。50°C)。来自N的内源X–C O物种甲基取代的酰胺基溶剂[Me 2 N–C(O)–R],尤其是PolarClean,以及原位形成的甲硅烷基甲酸酯的O-甲酰基[ OC – O (H)–H]如密度泛函理论(DFT)计算和同位素标记实验所证明的那样,在用于还原的CO 2插入的已用氢硅烷的活化中,显着的促进作用。此外,还描述了反应机理和基于条件的敏感性评估。
  • Visible-light-induced aerobic oxidative desulfurization of 2-mercaptobenzimidazoles <i>via</i> a sulfinyl radical
    作者:Mei Fu、Xiaochen Ji、Yongtong Li、Guo-Jun Deng、Huawen Huang
    DOI:10.1039/d0gc02269a
    日期:——
    A mild transition-metal-free non-toxic aerobic photoredox system was found to enable highly efficient desulfurization of 2-mercaptobenzimidazoles. This viable catalytic system includes Rose Bengal in a low catalyst loading as a photosensitizer and cheap, non-toxic NaCl in a catalytic amount as an additive, combined with an oxygen atmosphere. This protocol provides an important alternative access to
    发现温和的不含过渡金属的无毒需氧光氧化还原系统可实现2-巯基苯并咪唑的高效脱硫。这种可行的催化系统包括低催化剂含量的Rose Bengal作为光敏剂,以及廉价的无毒NaCl(催化量)作为添加剂,并与氧气气氛相结合。该方案提供了重要的替代途径,可以以通常的高收率获得各种苯并咪唑和氘代苯并咪唑产品,并且对各种合成和药学上有用的功能具有良好的耐受性。机理研究表明,单电子转移和能量转移都可能在初始步骤发生,并且亚硫酰基自由基中间体参与了关键的脱硫过程。
查看更多